Passage BIO, Inc. (PASG): Shareholders' Equity
$18.75M
As of 2025-12-31
$4.46M
As of 2026-06-30
-54.7%
3-year compound annual growth
-42.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.75M | -69.4% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $61.26M | -45.0% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $111.28M | -44.7% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $201.37M | -36.8% | 2024-03-04, Balance as of period end |
| 2021-12-31 | $318.66M | +4.6% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $304.71M | n/m | 2022-03-03, Balance as of period end |
| 2019-12-31 | -$56.25M | n/a | 2021-03-03, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Passage BIO, Inc. (PASG) | 2025-12-31 | $18.75M | -69.4% |
| Elutia Inc. (ELUT) | 2025-12-31 | $27.67M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $45.39M | -45.3% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$14.27M | n/m |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.47M | n/m |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $5.59M | -78.2% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | -$218.60M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $62.53M | +59.9% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $34.27M | +82.8% |
Compare PASG, ELUT, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗